Financial Data and Key Metrics Changes - For the fourth quarter, revenue was $76.2 million, an increase of 26% year-over-year. For the full year, revenue totaled $270.3 million, up approximately 21% compared to 2024 [18] - Adjusted EBITDA for the fourth quarter was $18.2 million, with a full-year record of $61.4 million, representing a margin of approximately 22.7% [21] - Free cash flow totaled $28.1 million for the year, more than doubling from $11.6 million in 2024 [22] Business Line Data and Key Metrics Changes - Equipment and supply sales increased by $19.4 million or approximately 63% year-over-year, driven by sleep resupply and maternal health contributions [19] - Ventilator rentals increased by $12.2 million, or roughly 10%, reflecting higher patient volumes [20] - PAP therapy patient count reached 34,528, representing growth of 62% year-over-year, with new sleep patient setups increasing 70% compared to the prior year [10] Market Data and Key Metrics Changes - Maternal health contributed approximately $9 million to revenue in 2025, strengthening diversification and reducing concentration on Medicare [14] - The company ended the year with 1,382 employees, reflecting disciplined workforce growth [5] Company Strategy and Development Direction - The company aims to build a cash-generating home care platform with multiple growth engines, focusing on high-touch clinical models and technology-enabled approaches [4] - Maternal health is viewed as a scalable extension of the platform and an important long-term growth opportunity [15] - The company is investing in compliance capabilities and operational efficiencies to navigate regulatory changes effectively [7][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity, citing strong early signals in the business as they enter 2026 [4] - The updated National Coverage Determination (NCD) is expected to reduce uncertainty and position the company favorably in the market [8] - The company anticipates net revenue in the range of $310 million to $320 million for 2026, representing approximately 17% year-over-year growth [26] Other Important Information - The company has authorized a new share repurchase program for 2026, reflecting confidence in cash flows and long-term outlook [24] - The balance sheet shows $13.5 million in cash and approximately $46 million available under credit facilities, with effectively no net debt [23] Q&A Session Summary Question: What is the top priority for the Lehan's acquisition expansion? - Management indicated that expanding the payer network is the top priority, along with training sales personnel to support growth [33][34] Question: How comfortable is the sales force with training and expansion? - Management confirmed that cross-training of sales representatives is underway, with a focus on integrating new product lines into existing sales strategies [36][38] Question: How will margin stability be maintained with a diversified revenue stream? - Management noted that scalability in general and administrative expenses, along with increased transaction volumes, will help maintain margin stability [39][40] Question: What are the key assumptions underlying the current revenue guidance? - Management clarified that while vent growth is not expected to be aggressive due to NCD adjustments, significant growth is anticipated in sleep and maternal health segments [46][47] Question: How does the reduction in respiratory therapists affect service revenue? - Management explained that the number of respiratory therapists is driven by patient volumes and that they expect growth in both therapists and patient volumes in 2026 [48]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $249.3 million, with subscription revenue representing 53% of total revenue, up from 45% in 2024 [12][13] - In Q4 2025, total revenue was $55.3 million, a 22.1% year-over-year decline, with subscription revenue at $28.8 million, down 22% year-over-year [13][14] - Adjusted EBITDA for Q4 was a loss of $10.3 million, an improvement from a loss of $12.7 million in Q3 2025 and a 55% improvement from $22.8 million in Q4 2024 [16] - Net loss for Q4 was $25.2 million, compared to $30.7 million in Q3, representing a 43.5% improvement year-over-year [16] Business Line Data and Key Metrics Changes - Amwell Medical Group (AMG) visit revenue was $23.7 million in Q4, down 18.7% year-over-year, reflecting the sale of APC and remaining churn from 2024 [14] - Paid AMG visits were flat at approximately 340,000 in Q4, while total platform visits were 1 million, down 28.4% year-over-year from 1.4 million visits in Q4 2024 [14] Market Data and Key Metrics Changes - The healthcare landscape is shifting towards operational efficiency, with payers and health systems pursuing platform consolidation and automation [3][4] - The Medicare population is aging, pharmacy costs are surging, and clinician shortages are worsening, creating a demand for technology-enabled care [4][5] Company Strategy and Development Direction - The company has focused exclusively on offering the best tech platform in the market, transitioning from a telehealth provider to a trusted enterprise infrastructure [9][10] - The strategy includes divesting non-core activities and restructuring to reduce costs, with a goal of cash flow breakeven from operations in Q4 2026 [10][11] - The company aims to leverage AI to enhance patient experience and improve operational efficiencies [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about achieving cash flow breakeven in Q4 2026, supported by a strong recurring revenue base and healthy cash reserves [11][17] - The company anticipates continued demand for its platform as AI-driven clinical programs grow and payers seek efficient infrastructure [19][28] Other Important Information - The company reported cash burn of approximately $19 million in Q4, ending the year with about $182 million in cash and marketable securities, and no debt [16][17] - For 2026, the company expects revenue in the range of $195 million to $205 million, with adjusted EBITDA losses between $24 million and $18 million [17][18] Q&A Session Summary Question: Thoughts on existing client contracts and government opportunities - Management noted that most contracts signed in 2025 were renewals, with fewer open renewals in 2026, except for the DHA renewal expected in summer [21][22] Question: Impact of new AI companies and trends on healthcare - Management is optimistic about AI's impact on healthcare, emphasizing the need for a consistent, regulated infrastructure to integrate multiple AI programs [24][26][28] Question: Headwinds and tailwinds for 2026 guidance - Tailwinds include earlier adoption of technology-enabled platforms, while headwinds involve the upcoming DHA renewal [31][33] Question: Details on DHA revenue step down and potential recovery - Management confirmed a step down in DHA revenue due to the elimination of certain programs but expressed confidence in renewing the contract and potentially adding those programs back [34][36] Question: Growth potential and market focus for 2026 - Management highlighted the strong secular trend towards technology-enabled care and the potential for same-store growth, particularly in the government sector [40][42][44]

Financial Data and Key Metrics Changes - Total revenue for Q1 was $66.8 million, a 12% increase compared to Q1 2024, and a 25% increase when normalizing for the sale of Amwell Psychiatric Care [23][24] - Subscription software revenue accounted for 48% of total revenue at $32.2 million, up 30% year-over-year [24][29] - Adjusted EBITDA improved to negative $12.2 million from negative $45.6 million in Q1 2024, reflecting ongoing cost reduction efforts [29] Business Line Data and Key Metrics Changes - The company completed approximately 1.3 million visits in Q1, which is about 23% lower than the previous year, but normalized visits were only 21% lower [25] - AMG's visit revenue trended 14.3% lower year-over-year at $26.6 million, but normalized visits were up 6.6% [26] - Average revenue per visit was $71, which is 8% lower compared to last year's Q1, but normalized revenue per visit was 8% higher [26] Market Data and Key Metrics Changes - The company is experiencing a shift towards technology-enabled care, with increasing consumer demand for online healthcare services [15][21] - The military health system is now fully utilizing the platform for virtual visits, positioning the company strongly in the federal market [11][12] Company Strategy and Development Direction - The company aims to achieve positive cash flow from operations by 2026, focusing on increasing the mix of subscription software revenues [6][30] - The recent hire of Dan Zemanski as Chief Product and Technology Officer is expected to enhance the company's technological capabilities and streamline consumer experiences [10][40] - The company is committed to driving efficiencies and optimizing cash flow while expanding its market presence [11][20] Management's Comments on Operating Environment and Future Outlook - Management noted that despite macroeconomic uncertainties, the demand for their platform is increasing as it provides significant ROI for clients [52][63] - The company remains confident in the renewal of its contract with the Defense Health Agency, which is expected to be finalized soon [32][70] - Management expressed optimism about the future, highlighting the potential for growth in technology-enabled care [21][35] Other Important Information - The company ended Q1 with $222 million in cash and marketable securities and zero debt [29] - The guidance for 2025 includes expected revenue in the range of $250 million to $260 million, with subscription revenue anticipated to represent nearly 60% of total revenues [30][31] Q&A Session Summary Question: Can you talk about bookings trends for CONVERGE and the impact of Dan's hire? - Management noted good receptivity to the platform beyond the DHA, with Dan's expertise expected to enhance consumer experience and data infrastructure [37][39] Question: Is the current gross margin rate sustainable for the rest of the year? - Management indicated that gross margins should improve as software revenues increase, with expectations of reaching 75-90% margins [44][45] Question: Have macroeconomic factors impacted sales timelines? - Management acknowledged market uncertainty but emphasized that their platform is seen as a solution to efficiency and revenue growth [51][53] Question: What is the status of the DHA contract and other government opportunities? - Management expects no significant changes in the economics of the DHA contract and highlighted the successful implementation of their platform across the military health system [56][58] Question: What is the company's direct exposure to tariffs? - Management stated that direct exposure to tariffs is minimal, as most hardware is sourced from third parties, and the business primarily focuses on software [62][63] Question: How is churn being managed, and what is the outlook for the selling season? - Management reported lower-than-expected churn and noted increased interest from both health systems and payers in their products [82][84]